Bruce Neal's Publications

Juraschek SP, Wang D, McEvoy JW et alii
Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE
Journal articles
2022
International Journal of Cardiology
Liao J, Kang A, Xia C et alii
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial
Journal articles
2022
Diabetes and Metabolism
Barraclough JY, Yu J, Figtree GA et alii
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial
Journal articles
2022
Diabetes
Sen T, Koshino A, Neal B et alii
Mechanisms of action of the SGLT2 inhibitor canagliflozin on tubular inflammation and damage: a post-hoc mediation analysis of the CANVAS trial.
Journal articles
2022
Diabetes Obes Metab
Nadkarni GN, Takale D, Neal B et alii
A Post Hoc Analysis of KidneyIntelXTM and Cardiorenal Outcomes in Diabetic Kidney Disease
Journal articles
2022
Kidney360
Li C, Yu J, Hockham C et alii
Canagliflozin and Atrial Fibrillation in Type 2 Diabetes Mellitus: A secondary analysis from the CANVAS Program and CREDENCE trials and meta-analysis.
Journal articles
2022
Diabetes Obes Metab
Campbell NRC, Whelton PK, Orias M et alii
2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action
Journal articles
2022
JOURNAL OF HUMAN HYPERTENSION
Li KC, Huang L, Tian M et alii
Cost-Effectiveness of a Household Salt Substitution Intervention: Findings From 20 995 Participants of the Salt Substitute and Stroke Study
Journal articles
2022
Circulation
Neuen BL, Oshima M, Agarwal R et alii
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
Journal articles
2022
Circulation
Schutte AE, Neal B
The sodium hidden in medication: a tough pill to swallow
Journal articles
2022
European heart journal
Yu J, Li J, Leaver PJ et alii
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial
Journal articles
2022
Cardiovascular research
Yin X, Rodgers A, Perkovic A et alii
EFFECTS OF SALT SUBSTITUTES ON BLOOD PRESSURE AND CLINICAL OUTCOMES IN DIFFERENT POPULATION GROUPS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Conference Abstracts
2022
in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Bhat S, Coyle DH, Trieu K et alii
Reply to A Coskun and B Oz
Journal articles
2022
Advances in Nutrition
Vaduganathan M, Sattar N, Xu J et alii
Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin
Journal articles
2022
Journal of the American College of Cardiology
Waijer SW, Sen T, Arnott C et alii
Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease
Journal articles
2022
Clinical journal of the American Society of Nephrology : CJASN
Coyle DH, Shahid M, Dunford EK et alii
The Contribution of Major Food Categories and Companies to Household Purchases of Added Sugar in Australia
Journal articles
2022
Journal of the Academy of Nutrition and Dietetics
Heerspink HJL, Oshima M, Zhang H et alii
Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial
Journal articles
2022
American Journal of Kidney Diseases
Canoy D, Copland E, Nazarzadeh M et alii
Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials
Journal articles
2022
HEART
Lam D, Nadkarni GN, Mosoyan G et alii
Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial
Journal articles
2022
American Journal of Nephrology
Marklund M, Gupta R, Tullu FT et alii
Abstract 019: Estimated Benefits And Risks Of Lowering Sodium Through Potassium-enriched Salt Substitution In India: A Modeling Study
Journal articles
2022
Circulation
RASMUSSEN D, Frederiksen P, Jatkoe A T et alii
POS-392 CANAGLIFLOZIN TREATMENT IMPACTS COLLAGEN TYPE III DEGRADATION AND FORMATION IN THE CANAGLIFLOZIN CARDIOVASCULAR ASSESSMENT STUDY (CANVAS)
Journal articles
2022
Kidney International Reports
Neal B, Tian M, Wu Y
Salt Substitute and Cardiovascular Events and Death. Reply
Journal articles
2021
The New England journal of medicine
Neuen BL, Oshima M, Perkovic V et alii
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: The CREDENCE trial
Journal articles
2021
European Heart Journal
Liu Y, Chu H, Peng K et alii
Factors Associated with the Use of a Salt Substitute in Rural China
Journal articles
2021
JAMA Network Open
Sen T, Li J, Neuen BL et alii
Association between circulating gdf-15 and cardio-renal outcomes and effect of canagliflozin: Results from the canvas trial
Journal articles
2021
Journal of the American Heart Association
Golledge J, Arnott C, Moxon J et alii
Protocol for the Metformin Aneurysm Trial (MAT): a placebo-controlled randomised trial testing whether metformin reduces the risk of serious complications of abdominal aortic aneurysm
Journal articles
2021
Trials

Bruce Neal's Publications

Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE

The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial

Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial

Mechanisms of action of the SGLT2 inhibitor canagliflozin on tubular inflammation and damage: a post-hoc mediation analysis of the CANVAS trial.

A Post Hoc Analysis of KidneyIntelXTM and Cardiorenal Outcomes in Diabetic Kidney Disease

Canagliflozin and Atrial Fibrillation in Type 2 Diabetes Mellitus: A secondary analysis from the CANVAS Program and CREDENCE trials and meta-analysis.

2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action

Cost-Effectiveness of a Household Salt Substitution Intervention: Findings From 20 995 Participants of the Salt Substitute and Stroke Study

Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials

The sodium hidden in medication: a tough pill to swallow

Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial

EFFECTS OF SALT SUBSTITUTES ON BLOOD PRESSURE AND CLINICAL OUTCOMES IN DIFFERENT POPULATION GROUPS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Reply to A Coskun and B Oz

Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin

Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease

The Contribution of Major Food Categories and Companies to Household Purchases of Added Sugar in Australia

Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial

Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials

Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial

Abstract 019: Estimated Benefits And Risks Of Lowering Sodium Through Potassium-enriched Salt Substitution In India: A Modeling Study

POS-392 CANAGLIFLOZIN TREATMENT IMPACTS COLLAGEN TYPE III DEGRADATION AND FORMATION IN THE CANAGLIFLOZIN CARDIOVASCULAR ASSESSMENT STUDY (CANVAS)

Salt Substitute and Cardiovascular Events and Death. Reply

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: The CREDENCE trial

Factors Associated with the Use of a Salt Substitute in Rural China

Association between circulating gdf-15 and cardio-renal outcomes and effect of canagliflozin: Results from the canvas trial

Protocol for the Metformin Aneurysm Trial (MAT): a placebo-controlled randomised trial testing whether metformin reduces the risk of serious complications of abdominal aortic aneurysm

The George Institute for Global Health

The George Institute country sites:

Acknowledgement of Country